# Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants

> **NCT03131895** · PHASE1 · COMPLETED · sponsor: **Takeda** · enrollment: 116 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** 30 mg dexlansoprazole capsules manufactured at TOB
- **DRUG:** 30 mg dexlansoprazole capsules manufactured at TPC
- **DRUG:** 60 mg dexlansoprazole capsules manufactured at TOB
- **DRUG:** 60 mg dexlansoprazole capsules manufactured at TPC

## Key facts

- **NCT ID:** NCT03131895
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-25
- **Primary completion:** 2017-07-03
- **Final completion:** 2017-07-31
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2019-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03131895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03131895, "Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03131895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*